Effect of rabeprazole combined with mosapride on chronic gastritis
雷贝拉唑联合莫沙必利治疗慢性胃炎的效果研究

摘要

目的 观察在对慢性胃炎患者进行治疗中按照莫沙必利、雷贝拉唑共同进行治疗的效果。方法按照纳入病例对比治疗观察的方式开展探究，共计选入患者60例，开展时间为2021年2月至2022年5月，盲选均分为对照组（30例，常规治疗）和观察组（30例，以莫沙必利、雷贝拉唑治疗）。分析治疗效果。结果 结合对两组恶心呕吐症状改善用时、嗳气缓解时间以及疼痛缓解时间对比，观察组均短于对照组，P<0.05。对比两组血C反应蛋白水平、白介素-6以及白介素-10水平，治疗前两组无差异，P>0.05，治疗后观察组优于对照组，P<0.05。结论 在对慢性胃炎患者进行治疗的过程中按照莫沙必利、雷贝拉唑进行治疗，可以促使患者对应症状迅速改善，并降低患者体内炎性反应水平，有助于患者恢复。

Abstract

Objective To observe the effect of mosapride and rabeprazole in the treatment of chronic gastritis.
Methods According to the way of comparative treatment and observation of included cases, 60 patients were selected in total, and the time was from February 2021 to May 2022. The blind selection was divided into the control group (30 cases, conventional treatment) and the observation group (30 cases, treated with mosapride and rabeprazole). Analyze the treatment effect.
Results Compared with the control group, the improvement time of nausea and vomiting symptoms, belching relief time and pain relief time in the observation group were shorter than those in the control group (P<0.05). Compared the levels of serum C-reactive protein, interleukin-6 and interleukin-10 between the two groups, there was no difference between the two groups before treatment (P>0.05), and the observation group was superior to the control group after treatment (P<0.05).
Conclusion   Mosapride and rabeprazole can promote the rapid improvement of corresponding symptoms, reduce the level of inflammatory reaction in patients with chronic gastritis, and help patients recover.